pubmed.ncbi.nlm.nih.gov

The mechanisms behind the therapeutic activity of BET bromodomain inhibition - PubMed

  • ️Wed Jan 01 2014

Review

The mechanisms behind the therapeutic activity of BET bromodomain inhibition

Junwei Shi et al. Mol Cell. 2014.

Abstract

The bromodomain and extraterminal (BET) protein Brd4 recruits transcriptional regulatory complexes to acetylated chromatin. While Brd4 is considered to be a general transcriptional regulator, pharmacological inhibition of BET proteins shows therapeutic activity in a variety of different pathologies, particularly in models of cancer and inflammation. Such effects have been attributed to a specific set of downstream target genes whose expression is disproportionately sensitive to pharmacological targeting of BET proteins. Emerging evidence links the transcriptional consequences of BET inhibition to the association of Brd4 with enhancer elements, which tend to be involved in lineage-specific gene regulation. Furthermore, Brd4 engages in direct regulatory interactions with several DNA-binding transcription factors to influence their disease-relevant functions. Here we review the current understanding of molecular mechanisms that underlie the promising therapeutic effects of BET bromodomain inhibition.

Copyright © 2014 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Domain architecture of human Brd4 and other BET proteins

Three isoforms of Brd4 are indicated. ET: extra-terminal domain. CTD: C-terminal domain. Isoform B of Brd4 has a unique C-terminus, which interacts with condensin II complexes (Floyd et al., 2013). Brdt and Brd2 have multiple isoforms, which are not indicated here. In some studies, the CTD of Brd4 and Brdt is referred to as a C-terminal motif (CTM).

Figure 2
Figure 2. Protein-protein interactions involving Brd4

Depicted are some of the critical protein-protein interactions employed by Brd4 that could be relevant to the therapeutic effects of BET inhibitors. Mediator, Jmjd6, and P-TEFb are candidate effectors recruited by Brd4 to regulate transcription by Pol II. Acetylated histones and/or TFs have been suggested as potential recruiters of Brd4 to promoters and/or enhancer regions.

Figure 3
Figure 3. Lineage-specific arrangements of Brd4-occupied enhancers at the MYC locus that correlate with sensitivity to pharmacological BET inhibition

Brd4 occupancy is represented by red triangles as measured by ChIP-seq in either MM1.S cells (top) (Loven et al., 2013) or in MLL-AF9/NrasG12D acute myeloid leukemia (Shi et al., 2013). In these two cell lines, MYC transcription is highly sensitive to BET inhibition.

Similar articles

Cited by

References

    1. Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II: emerging roles in metazoans. Nature reviews. Genetics. 2012;13:720–731. - PMC - PubMed
    1. Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, et al. BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. Cell. 2013;154:569–582. - PMC - PubMed
    1. Anders L, Guenther MG, Qi J, Fan ZP, Marineau JJ, Rahl PB, Loven J, Sigova AA, Smith WB, Lee TI, et al. Genome-wide localization of small molecules. Nature biotechnology. 2014;32:92–96. - PMC - PubMed
    1. Bandukwala HS, Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ, Molesworth AM, Smithers N, Lee K, Witherington J, et al. Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2012;109:14532–14537. - PMC - PubMed
    1. Banerjee C, Archin N, Michaels D, Belkina AC, Denis GV, Bradner J, Sebastiani P, Margolis DM, Montano M. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. Journal of leukocyte biology. 2012;92:1147–1154. - PMC - PubMed

Publication types

MeSH terms

Substances